Expressive

rs12143162 (LINC02796): linked to substance use disorder

Key takeaways

  • This variant is linked to substance use disorder with a reported effect size of 5.6 and p=2e-8 in about 1.5 million people.
  • It also shows increased expression of RPL31P12 in brain cerebellum according to GTEx data.
  • The association is based on GWAS catalog data.

Key takeaways

  • This variant is linked to substance use disorder with a reported effect size of 5.6 and p=2e-8 in about 1.5 million people.
  • It also shows increased expression of RPL31P12 in brain cerebellum according to GTEx data.
  • The association is based on GWAS catalog data.

What the research says This variant rs12143162 is associated with substance use disorder with a reported effect size 5.6 p=2e-8 in about 1.5 million individuals [41057643]. It also shows increased expression of RPL31P12 in brain cerebellum according to GTEx data [GTEx].

Reported associations

  • Substance use disorder: the variant is associated with higher risk as measured by effect size 5.6 p=2e-8 in about 1.5 million individuals [41057643].
  • RPL31P12 expression: increased expression in brain cerebellum [GTEx].

Evidence quality The supplied studies do not report a direct trait association for this variant; the rsid appears via GWAS catalog association [41057643]. The GTEx context provides tissue-specific expression effect but does not link to disease.

Tissue-specific expression effects

  • RPL31P12: increased expression in brain cerebellum GTEx Portal.

Lifestyle considerations No lifestyle considerations on file for this variant.

Frequently asked questions

What does rs12143162 mean?

It is a genetic variant linked to substance use disorder and also increases RPL31P12 expression in the brain.

Is this variant common?

The GWAS found it associated with about 1.5 million people, so it is relatively frequent.

Does it affect other genes?

It mainly influences RPL31P12 expression and has no known effect on other genes.